Form 4: Apimeds Pharmaceuticals US, Inc.: Director Hankil Yoon Acquires Stock Options
SEC Form 4
Director Hankil Yoon reports acquisition of stock options in Apimeds Pharmaceuticals US, Inc. on May 16, 2025.
Summary
- Hankil Yoon, a director of Apimeds Pharmaceuticals US, Inc., reported the acquisition of stock options on May 16, 2025.
- The options grant the right to buy 5,780 shares of common stock at an exercise price of $1.73 per share.
- The options vest fully on May 16, 2026, and expire on May 16, 2035.
- The transaction was reported on Form 4, filed with the SEC on May 20, 2025.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of stock option acquisition |
| 05/16/2026 | Stock options vest in full |
| 05/16/2035 | Stock options expiration date |
| 05/20/2025 | Date Form 4 was filed |
Keywords
stock options, Form 4, director, acquisition, Apimeds Pharmaceuticals US, Inc., Hankil Yoon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.